ArticleJournal of assisted reproduction and genetics2025
Single euploid embryo transfer outcomes following cancer and systemic chemotherapy.
Article in Journal of assisted reproduction and genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSystemic chemotherapy may impair future reproduction due to its gonadotoxic effects. There are limited data on pregnancy outcomes in patients with a history of chemotherapy who undergo single euploid embryo transfer (SEET). MATERIALS AND
methodsThis retrospective cohort study included patients with prior chemotherapy who underwent SEET from 2011 to 2023. Cycles were matched 1:3 with controls by oocyte age, age at SEET, BMI, and year. Wilcoxon rank, chi-square, and adjusted logistic regression were used for analysis. A sub-analysis was performed to compare patients who had SEET using oocytes retrieved pre- and post-chemotherapy.
resultsFifty-five cycles from 32 patients with prior chemotherapy were matched to 165 control cycles. In the chemotherapy group, 23 cycles (41.8%) used embryos derived from oocytes pre-chemotherapy, while 32 cycles (58.2%) used embryos derived from oocytes post-chemotherapy. Endometrial thickness was significantly lower with prior chemotherapy vs. controls (8 mm vs 9 mm, respectively; p = 0.02). Ongoing pregnancy/live birth rate was similar in patients with prior chemotherapy and controls (56.4% vs. 57.0%, p = 0.94). Adjusted analysis confirmed the findings (aOR 1.5, CI 0.79-2.8, p = 0.21). Pregnancy, clinical pregnancy, and loss rates were similar. The subgroup analysis showed no statistical difference in outcomes in patients who used pre-chemotherapy vs. post-chemotherapy oocytes. However, a trend towards poorer outcomes in patients who used post-chemotherapy oocytes was observed.
conclusionsOutcomes after SEET in patients with prior chemotherapy are comparable to controls. A possible trend toward reduced success using post-chemotherapy oocytes warrants further investigation. Understanding the potential mechanisms by which chemotherapy may affect future fertility is important for survivorship care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.